The neuropsychological outcome of pediatric patients with refractory epilepsy treated with VNS — A 24-month follow-up in Taiwan

Tsai, Jeng-Dau; Chang, Ying-Chao; Lin, Lung‐Chang; Hung, Kun-Long

doi:10.1016/j.yebeh.2015.12.030

Cited by 23 publications

(21 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PuLsE (open prospective randomized long-term effectiveness) trial demonstrated that VNS therapy, adjunct to the best medical practice (BMP) in patients with drug-resistant focal seizures, was associated with a significant improvement in quality of life compared with BMP alone [ 94 ]. These data are widely confirmed by the literature [ 18 , 90 , 91 , 94 , 95 , 96 , 97 , 98 , 99 ]. The main findings after VNS therapy are the following: reduction in seizure frequency; improvement in verbal and figure recognition; increased experiences of attention and arousal; memory consolidation; cognitive flexibility and creativity; and decision-making [ 92 , 93 , 100 , 101 , 102 ].…”

Section: Resultssupporting

confidence: 85%

Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy

Marras

Colicchio

Palma

et al. 2020

IJERPH

View full text Add to dashboard Cite

Background: Vagus nerve stimulation (VNS) is a palliative treatment for medical intractable epileptic syndromes not eligible for resective surgery. Health technology assessment (HTA) represents a modern approach to the analysis of technologies used for healthcare. The purpose of this study is to assess the clinical, organizational, financial, and economic impact of VNS therapy in drug-resistant epilepsies and to establish the congruity between costs incurred and health service reimbursement. Methods: The present study used an HTA approach. It is based on an extensive detailed bibliographic search on databases (Medline, Pubmed, Embase and Cochrane, sites of scientific societies and institutional sites). The HTA study includes the following issues: (a) social impact and costs of the disease; (b) VNS eligibility and clinical results; (c) quality of life (QoL) after VNS therapy; (d) economic impact and productivity regained after VNS; and (e) costs of VNS. Results: Literature data indicate VNS as an effective treatment with a potential positive impact on social aspects and on quality of life. The diagnosis-related group (DRG) financing, both on national and regional levels, does not cover the cost of the medical device. There was an evident insufficient coverage of the DRG compared to the full cost of implanting the device. Conclusions: VNS is a palliative treatment for reducing seizure frequency and intensity. Despite its economic cost, VNS should improve patients’ quality of life and reduce care needs.

show abstract

Section: Resultssupporting

confidence: 85%

Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy

Marras

Colicchio

Palma

et al. 2020

IJERPH

View full text Add to dashboard Cite

show abstract

“…23 Tsai et al enrolled 37 patients and found seizure reduction rates of 45.9% at 12 months and 43.2% at 24 months, with one seizure-free patient (2.7%). 25 Li et al enrolled 30 patients and found seizure reduction rate of 42.6%, and 15 patients (50%) had S50% seizure reduction rate, with one seizurefree patient (3.3%). 26 Although the studies of Tsai et al and Li et al aimed to investigate the impact of VNS on neuropsychological outcome in children with RE and parenting stress, their seizure reduction outcomes are consistent with our study.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of children with refractory epilepsy after vagus nerve stimulation in Taiwan

Chiu

Hung

et al. 2020

Pediatrics & Neonatology

Self Cite

View full text Add to dashboard Cite

Background: Vagus nerve stimulation (VNS) is used as an add-on treatment for epilepsy. This study aimed to use Taiwanese nationwide registry data to analyze the therapeutic effects of VNS in children with refractory epilepsy (RE) and try to explore predictive factors of VNS treatment effectiveness. Methods: This retrospective study collected data from December 2007 to December 2014. Patient variables included gender, age, VNS implantation date, epilepsy duration, seizure frequency, seizure type, etiology, and antiepileptic drug (AED) history. We divided patients into three groups: Group I as seizure frequency >80 times per month, Group II as seizure frequency 24e80 times per month, and Group III as seizure frequency <24 times per month. Multivariate regression analysis was performed to determine predictors of seizure frequency reduction after VNS treatment. Results: A total of 80 patients were included in this study. Three or more AED types were prescribed for 61 (77.1%) patients. Seizure frequency decreased significantly at 12 and 24 months

show abstract

“…In the treatment of epilepsy including children and adults, VNS treatment has been proved safe and effective . Thus, the FDA has approved that VNS can be used in children over 4 years old recently . The VNS treatments do not only reduce the frequency of seizures but also reduce the psychological burden of children .…”

Section: Applicationmentioning

confidence: 99%

“…26 Thus, the FDA has approved that VNS can be used in children over 4 years old recently. [27][28][29][30][31] The VNS treatments do not only reduce the frequency of seizures but also reduce the psychological burden of children. 32 There is another study has reported that VNS may have a therapeutic effect on epilepsy patients <3 years old.…”

Section: Appli C Ati Onmentioning

confidence: 99%

Research progress of vagus nerve stimulation in the treatment of epilepsy

Fan

Shan

et al. 2019

CNS Neurosci Ther

View full text Add to dashboard Cite

The International League Against Epilepsy (ILAE) defined drug‐resistant epilepsy (DRE) that epilepsy seizure symptoms cannot be controlled with two well‐tolerated and appropriately chosen antiepileptic drugs, whether they are given as monotherapy or in combination. According to the WHO reports, there is about 30%‐40% of epilepsy patients belong to DRE. These patients need some treatments other than drugs, such as epilepsy surgery, and neuromodulation treatment. Traditional surgical approaches may be limited by the patient's clinical status, pathological tissue location, or overall prognosis. Thus, neuromodulation is an alternative choice to control their symptoms. Vagus nerve stimulation (VNS) is one of the neuromodulation methods clinically, which have been approved by the Food and Drug Administration (FDA). In this review, we systematically describe the clinical application, clinical effects, possible antiepileptic mechanisms, and future research directions of VNS for epilepsy.

show abstract

The neuropsychological outcome of pediatric patients with refractory epilepsy treated with VNS — A 24-month follow-up in Taiwan

Cited by 23 publications

References 32 publications

Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy

Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy

Therapeutic effects of children with refractory epilepsy after vagus nerve stimulation in Taiwan

Research progress of vagus nerve stimulation in the treatment of epilepsy

Contact Info

Product

Resources

About